newsfilter
← Latest News
GlobeNewswire·

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Topline results are expected to be announced in second half of calendar 2026 The company has had a pre-NDA meeting with the FDA and expects to submit an NDA in second half of calendar 2026 The company has received